Serious adverse events · women with persistent, recurrent, or metastatic cervical cancer
Cediranib plus chemotherapy showed no clear difference in serious adverse events compared with placebo plus chemotherapy (low certainty).
1 finding from 1 review
Serious adverse events · women with persistent, recurrent, or metastatic cervical cancer
Pazopanib plus lapatinib showed no clear difference in serious adverse events compared with lapatinib (low certainty).
1 finding from 1 review
Serious adverse events · women with persistent, recurrent, or metastatic cervical cancer
Pazopanib showed no clear difference in serious adverse events compared with lapatinib (low certainty).
1 finding from 1 review
Serious adverse events · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy probably leads to higher serious adverse events compared with chemotherapy (moderate certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline
The intervention showed no clear difference in serious adverse events (high certainty).
1 finding from 1 review
Total serious adverse events · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod showed no clear difference in total serious adverse events compared with cidofovir (moderate certainty).
1 finding from 1 review
Severe/serious adverse events · women with locally advanced cervical cancer
Hysterectomy (simple or radical) with radiotherapy may leads to higher severe/serious adverse events compared with radiotherapy alone (low certainty).
1 finding from 1 review
Severe/serious adverse events · women with locally advanced cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
People with serious adverse events · people with neutropenia or neutrophil dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events at up to 5‐year · 9‐ to 14‐year‐old females and males
It is very uncertain whether two doses of HPV vaccine with longer interval changes serious adverse events at up to 5‐year compared with two doses of HPV vaccine with shorter interval (very low certainty).
1 finding from 1 review
Serious adverse events at up to 3‐year · 10‐ to 26‐year‐old males
It is very uncertain whether three doses HPV vaccine changes serious adverse events at up to 3‐year compared with control (very low certainty).
1 finding from 1 review
Serious adverse events at up to 5‐year · 9‐ to 15‐year‐old females
It is very uncertain whether two doses of HPV vaccine changes serious adverse events at up to 5‐year compared with three doses of HPV vaccine (very low certainty).
1 finding from 1 review
Serious adverse events at up to 4.5‐year · 9‐ to 26‐year‐old females and males
Nonavalent HPV vaccine showed no clear difference in serious adverse events at up to 4.5‐year compared with quadrivalent HPV vaccine (low certainty).
1 finding from 1 review
Serious adverse events (range of outcomes) · adult women diagnosed with early stage (I to IIa) endometrial cancer undergoing surgery as primary treatment.
Laparoscopy showed no clear difference in serious adverse events (range of outcomes) compared with laparotomy (low certainty).
1 finding from 1 review
Specific adverse events: serious haemorrhage · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serious haemorrhage compared with placebo plus chemotherapy (very low certainty).
1 finding from 1 review
Specific adverse events: serioushypertension · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serioushypertension compared with placebo plus chemotherapy (very low certainty).
1 finding from 1 review
Specific adverse events: serious haemorrhage · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy may leads to higher specific adverse events: serious haemorrhage compared with chemotherapy (low certainty).
1 finding from 1 review
Intervention not reported
Number of serious adverse events ‐ pulmonary · treating infections in people with neutropenia or neutrophil dysfunction
It is very uncertain whether the intervention changes number of serious adverse events ‐ pulmonary (very low certainty).
1 finding from 1 review
Specific adverse events: serious thromboembolic events · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serious thromboembolic events compared with placebo plus chemotherapy (very low certainty).
1 finding from 1 review